• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Saccharolipids Saccharolipids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Saccharolipids

Introduction to Cuniloside B (CAS No: 1187303-40-7)

Cuniloside B, a naturally occurring compound with the chemical formula CAS No: 1187303-40-7, has garnered significant attention in the field of pharmaceutical research due to its unique structural properties and potential biological activities. This compound, which belongs to the flavonoid family, has been extensively studied for its therapeutic implications in various diseases, particularly in oncology and neurodegenerative disorders. The structural elucidation and pharmacological profiling of Cuniloside B have opened new avenues for drug development, making it a subject of intense interest among researchers.

The molecular structure of Cuniloside B features a glycosidic linkage between a flavonoid aglycone and a sugar moiety, which contributes to its solubility and bioavailability. This structural characteristic is crucial for its absorption and distribution within the body, making it an attractive candidate for therapeutic applications. Recent studies have highlighted the anti-inflammatory and antioxidant properties of Cuniloside B, which are attributed to its ability to scavenge free radicals and modulate inflammatory pathways.

One of the most compelling aspects of Cuniloside B is its potential role in cancer therapy. Preclinical studies have demonstrated that Cuniloside B can induce apoptosis in various cancer cell lines by inhibiting key signaling pathways such as PI3K/Akt and MAPK. These pathways are often dysregulated in cancer cells, leading to uncontrolled cell growth and survival. The ability of Cuniloside B to disrupt these pathways suggests its potential as a chemotherapeutic agent. Additionally, its selective toxicity towards cancer cells without significant toxicity to normal cells makes it an appealing candidate for further clinical development.

Another area where Cuniloside B has shown promise is in the treatment of neurodegenerative diseases. Research indicates that Cuniloside B can protect against neurotoxicity induced by oxidative stress and inflammation, which are hallmark features of conditions such as Alzheimer's disease and Parkinson's disease. Studies have shown that Cuniloside B can cross the blood-brain barrier, allowing it to exert its effects directly within the central nervous system. This property is critical for developing effective treatments for neurodegenerative disorders, where targeted delivery is essential.

The pharmacokinetic profile of Cuniloside B has also been a focus of recent research. Studies have shown that Cuniloside B exhibits moderate oral bioavailability, with a half-life that allows for repeated dosing regimens. This makes it feasible for clinical translation, provided that issues related to metabolism and excretion can be addressed. Efforts are underway to optimize the pharmacokinetic properties of Cuniloside B through structural modifications, which could enhance its therapeutic efficacy.

In conclusion, Cuniloside B (CAS No: 1187303-40-7) is a promising natural product with a wide range of potential applications in medicine. Its unique structural features and biological activities make it an attractive candidate for further research and development. As our understanding of its mechanisms of action continues to grow, so too does the potential for novel therapeutic interventions based on this compound. The ongoing studies into Cuniloside B highlight the importance of natural products in the discovery of new drugs and their potential to address some of the most challenging diseases faced by humanity.

• 36983-69-4(Actodigin)
• 82209-72-1(Andropanoside)
• 865887-46-3(Oleuropeic acid 8-O-glucoside)
• 27215-14-1(Neoandrographolide)
• 114613-59-1(17alpha-Thevebioside)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)